EPO and chronic kidney disease: Furthermore, EPO-induced up-regulation of FGF23 production has been demonstrated in CKD patients, kidney transplant recipients, and in animal models in which circulating EPO levels are elevated due to either endogenous or exogenous sources [14,33].